CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granulesWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug231 Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) Wiki 1.00

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D011014 Pneumonia NIH 0.08

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.15

There is one clinical trial.

Clinical Trials

1 Effects of Traditional Chinese Medicines (TCMs) on Patients With 2019-nCoV Infection: A Perspective, Open-labeled, Randomized, Controlled Trial

The aim of this study is to test whether Traditional Chinese Medicines (TCMs) are effective and safe for treating 2019-nCoV infection. After the enrolment of approximately 30 subjects, the recruitment will be paused, and planned interim analysis will be performed to preliminarily investigate the efficacy and safety of TCMs in patients infected with 2019-nCoV.

NCT04251871 Pneumonia Caused by Human Coronavirus (Disorder) Drug: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules Drug: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir)
MeSH:Pneumonia
HPO:Pneumonia

Primary Outcomes

Description: Symptoms associated with 2019-nCoV infection involve fever and cough.

Measure: Time to complete remission of 2019-nCoV infection-associated symptoms

Time: 28 days

Secondary Outcomes

Description: In eligible subjects, the oxygen saturation level is less than 94%, and the respiratory rate is more than 24 breaths per min.

Measure: The incidence of dyspnea with low oxygen saturation level and high respiratory rate

Time: 28 days

Description: Number of subjects who develop complications, including acute respiratory distress syndrome (ARDS), RNAaemia, acute cardiac injury, acute kidney injury (AKI), secondary infection and shock, will be described.

Measure: Number of subjects who develop complications of 2019-nCoV infection

Time: 28 days

Description: Virus shedding was detected twice at least a day apart.

Measure: Time to virus shedding

Time: 28 days

Description: improvement of chest radiographic evidence indirectly reflects recovery in patients infected with 2019-nCoV.

Measure: Time to improvement of abnormalities in Chest radiology

Time: 28 days

Description: The changes of TCM symptoms before and after treatment reveal the effect of TCM treatment for 2019-nCoV infection.

Measure: The evaluation of Traditional Chinese Medicine (TCM) symptoms before and after treatment

Time: 28 days

Other Outcomes

Description: The rate of subject who die will be described.

Measure: Rate of subjects who die

Time: 28 days

Description: The rate of subjects with severe 2019-nCoV infection who receive systematic corticosteroids will be described.

Measure: Rate of subjects receiving systematic corticosteroids

Time: 28 days

Description: The length of hospital stays

Measure: The length of hospital stays

Time: 28 days

Description: The duration of respiratory support including invasive and non-invasive mechanical ventilation

Measure: The duration of respiratory support

Time: 28 days

Related HPO nodes (Using clinical trials)

HP:0002090: Pneumonia
Genes 208
TIMM8A DNAH9 GAS8 DNAH11 TNFRSF11A TBC1D24 SPAG1 MS4A1 GAS2L2 CCDC151 NIPBL BTK LIG4 NFKB2 TCIRG1 IGLL1 RNF168 STAT3 TAF1 RSPH4A CFTR NME8 DNAAF4 LEP CCDC65 NADK2 CD55 COL11A2 NHLRC1 PEPD CFAP300 LTBP3 WAS DNAI1 TBCD IL2RG GFI1 NBN RSPH1 CCDC39 PMM2 ICOS TNFSF12 IFNGR1 CARD11 SFTPC DNAL1 OFD1 ZMYND10 IL21R FMO3 SLC35A1 PLOD1 ORC6 RAG2 CACNA1C GAS8 RYR1 CFAP298 GNPTAB TNFRSF13B KDM6A PANK2 RANBP2 CYBA USB1 UBB DOCK8 ADA DNAAF2 KMT2D SAMD9 MUC5B IL7R DNAAF1 ICOS RAG2 CARD11 PTPRC ALMS1 NOTCH3 NSMCE3 DNAI1 TNFRSF13C GRHL3 EGFR IL2RG DNAAF6 PNP DNAH5 SETBP1 CR2 CD3E ADA MASP2 SFTPA2 ACTA1 RAC1 TTC25 FCGR2A ZAP70 SPEF2 IGHM DNAAF5 NBN CD247 DDR2 CD19 ACADVL KIAA0586 TK2 BLNK ARMC4 SGCG RAG1 CXCR4 NCF1 SRP54 FOXP3 IRF8 CFAP221 RNU4ATAC KCNJ6 LRBA CD3D P4HTM SELENON CCDC114 TNFRSF13B PLG DCLRE1C SLC25A24 DCLRE1C ICOS IL7R FOXJ1 JAK3 IL2RG CASP8 RAG1 OSTM1 CFAP410 CCNO NCF2 UNC119 TNFRSF13C JAK3 RNF125 STK36 POLA1 CD19 CR2 DNAH1 RSPH3 RSPH9 CYBB DRC1 DCLRE1C CCDC103 DNAAF3 LRRC56 PIGN LRRC6 SP110 PRKCD ACP5 CCDC40 SLC35C1 BTK MTHFD1 PGM3 RAG1 TERT CHD7 CFB TGFB1 RNU4ATAC SMARCD2 NKX2-1 OFD1 ZBTB24 BTK DNAI2 WDR19 ZAP70 CD79B CD81 COL11A2 NFIX RAG2 ELANE AFF4 NFKB1 IL2RG TNFRSF13C TNFSF12 CCDC114 ADA GBA DNAJB13 RPGR CSPP1 RMRP EPM2A DNMT3B NFKB2 MCIDAS HYDIN
Protein Mutations 6
A2063G G551D K55R L460D R287Q S1009A
SNP 0